Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

- Management to host call and webcast today at 5:00 p.m. Eastern to discuss

financial results and recent business highlights -

SAN DIEGO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced unaudited financial results for the three and nine months ended September 30, 2008.

Three Months Ended September 30, 2008

As of September 30, 2008, Orexigen held $52.5 million in cash and cash equivalents and an additional $47.6 million in investment securities, available-for-sale, for a total balance of $100.1 million. Orexigen holds primarily treasury-backed securities, money market funds and agency instruments guaranteed by the U.S. federal government. The Company's exposure to corporate debt instruments is modest, and comprised exclusively of commercial paper rated at least A1+/P1, with average maturity less than 90 days. The Company does not have any auction rate securities on its balance sheet.

For the three months ended September 30, 2008, Orexigen reported a net loss of $24.8 million, or $0.72 per share attributable to common stockholders, as compared to a net loss of $14.5 million, or $0.54 per share attributable to common stockholders, for the comparable period in 2007.

Total operating expenses for the three months ended September 30, 2008 were $25.1 million compared to $15.6 million for the comparable period in 2007. The increased operating expenses were due primarily to an $8.6 million increase in research and development expenses in connection with the Company's Contrave(R) Phase 3 clinical trials, related proprietary product for
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... BOSTON , Aug. 28, 2014  Next month, executives ... at three key industry events beginning with Patient-Centered Clinical ... Hotel in Boston , September 4-5. Patient ... , and Aaron Fleishman will share insights on ... how a variety of tactics – from media to mobile ...
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Years Recognizes Breakthrough ... of Heart Disease, ABBOTT PARK, Ill., Oct. 28 ... Innovation Award for its XIENCE V(TM),Everolimus Eluting Coronary Stent ... data, the next-generation drug eluting stent,represents a significant advance ...
... Oct. 28 Volcano Corporation,(Nasdaq: VOLC ), a ... the diagnosis and treatment of coronary and peripheral artery,disease, ... for the,third quarter and first nine months of fiscal ... a conference call to discuss its financial,results and operating ...
... 28 Sirnaomics, Inc., (http://www.sirnaomics.com ) announced ... SBIR,(small business innovation research) grant from National ... Sirnaomics, Inc., a,biopharmaceutical company founded in early ... Technology for novel targeted therapeutic,development. The company,s ...
Cached Biology Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 2Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 3Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 3
(Date:8/29/2014)... the repeated climatic shifts over the last 120,000 ... diversity, a team of researchers led by City ... developed a new biodiversity metric called "phylogeographic endemism." ... genetic variation within species is restricted in geographical ... biology, and 14 other researchers from institutions in ...
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... the prolific bloomer Emiliania huxleyi , can grow ... finding contradicts the common view that E. huxleyi ... supplies of thiamine in the ocean to survive. , ... ocean," says CIFAR Senior Fellow Alexandra Worden , ... CIFAR fellows John Archibald (Dalhousie University), ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... keeper of the world,s shark attack records, is also now ... the sawfish. Distinguished by a long rostrum or "saw" ... its name, the sawfish has become a historical and cultural ... ichthyologist and curator of both the International Shark Attack File ...
... Geosphere , The Geological Society of America,s e-journal, ... multiple fields, including tectonics, oceanography, sedimentology, and paleontology, to ... to 6 million years ago; sedimentation in a piggyback ... Nevada; and a study of the South Balkan extensional ...
... Calif. For their landmark research leading to the ... flood-prone areas worldwide, Julia Bailey-Serres of UC ... David Mackill of the International Rice Research ... U.S. Department of Agriculture (USDA) with the 2008 USDA ...
Cached Biology News:Endangered sawfish focus of national collection and recovery efforts 2December Geosphere media highlights 2December Geosphere media highlights 3UC Riverside rice geneticist receives high honor from US Department of Agriculture 2UC Riverside rice geneticist receives high honor from US Department of Agriculture 3
... IS System is ideal for developing single ... This system contains the new, improved, and ... The user can design specific templates for ... has fully integrated graphing and data regression ...
... Sweep- based acquision and analysis ... response type applications. Contains powerful ... flexible analysis functions including automated ... plotting. Also includes many electrophysiology ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: